NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
CAMBRIDGE, Mass., Feb. 02, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at the following investor conferences in February:
- Leerink Partners Global Healthcare Conference (fireside chat format) on Wednesday, February 15, 2017 at 10:30 a.m. ET in New York City; and,
- RBC Capital Markets Global Healthcare Conference (fireside chat format) on Thursday, February 23, 2017 at 8:30 a.m. ET in New York City.
Replays of the webcasts of the presentations can be accessed at the investor section of http://www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Contact: Monique Allaire, THRUST IR 617.895.9511 [email protected]
